HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%

Reuters10-01

HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%

Net asset value $(NAV)$ per share increased by 16.4% in the second quarter of fiscal year 2025/2026 to CHF 251.78. The company reported a quarterly profit of CHF 236 million, offsetting the currency-related loss from the first quarter. For the first half of the current fiscal year, the company expects a profit of CHF 96 million and an increase in NAV of 6.1% in Swiss francs (17.8% in US dollars). The share price rose by 4.0% during the same period and trades at a 28% discount to NAV. The positive second quarter results are mainly attributed to developments in listed portfolio companies, including clinical study results from Abivax, Mineralys, Upstream Bio, and UniQure, as well as acquisition offers for Merus, Y-mAbs Therapeutics, and 89Bio. Foreign currency effects had no material impact on the second quarter's performance. The final half-year results will be published on October 24, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2207074_de), on October 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2572535555?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 23:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572535555","market":"nz","top_or_hot":-1,"title":"HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Net asset value <a href=\"https://laohu8.com/S/NAV\">$(NAV)$</a> per share increased by 16.4% in the second quarter of fiscal year 2025/2026 to CHF 251.78. The company reported a quarterly profit of CHF 236 million, offsetting the currency-related loss from the first quarter. For the first half of the current fiscal year, the company expects a profit of CHF 96 million and an increase in NAV of 6.1% in Swiss francs (17.8% in US dollars). The share price rose by 4.0% during the same period and trades at a 28% discount to NAV. The positive second quarter results are mainly attributed to developments in listed portfolio companies, including clinical study results from Abivax, Mineralys, Upstream Bio, and UniQure, as well as acquisition offers for Merus, Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, and 89Bio. Foreign currency effects had no material impact on the second quarter's performance. The final half-year results will be published on October 24, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2207074_de), on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-01 23:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Net asset value <a href=\"https://laohu8.com/S/NAV\">$(NAV)$</a> per share increased by 16.4% in the second quarter of fiscal year 2025/2026 to CHF 251.78. The company reported a quarterly profit of CHF 236 million, offsetting the currency-related loss from the first quarter. For the first half of the current fiscal year, the company expects a profit of CHF 96 million and an increase in NAV of 6.1% in Swiss francs (17.8% in US dollars). The share price rose by 4.0% during the same period and trades at a 28% discount to NAV. The positive second quarter results are mainly attributed to developments in listed portfolio companies, including clinical study results from Abivax, Mineralys, Upstream Bio, and UniQure, as well as acquisition offers for Merus, Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, and 89Bio. Foreign currency effects had no material impact on the second quarter's performance. The final half-year results will be published on October 24, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2207074_de), on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL5tnLj9:1","article_id":"2572535555","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572535555","pubTimestamp":1759333787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Net asset value  per share increased by 16.4% in the second quarter of fiscal year 2025/2026 to CHF 251.78. The company reported a quarterly profit of CHF 236 million, offsetting the currency-related loss from the first quarter. For the first half of the current fiscal year, the company expects a profit of CHF 96 million and an increase in NAV of 6.1% in Swiss francs . The share price rose by 4.0% during the same period and trades at a 28% discount to NAV. The positive second quarter results are mainly attributed to developments in listed portfolio companies, including clinical study results from Abivax, Mineralys, Upstream Bio, and UniQure, as well as acquisition offers for Merus, Y-mAbs Therapeutics, and 89Bio. Foreign currency effects had no material impact on the second quarter's performance. The final half-year results will be published on October 24, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","QURE":"uniQure N.V.","ETNB":"89Bio, Inc.","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","UPB":"UpStream Bio Inc.","YMAB":"Y-mAbs Therapeutics, Inc.","MRUS":"Merus B.V.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"HBM Healthcare Investments报告季度利润2.36亿瑞士法郎，资产净值增长16.4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":0.9,"MRUS":0.9,"UPB":0.9,"YMAB":0.9,"ETNB":0.9},"content_text":"HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%\n    \n\n        Net asset value $(NAV)$ per share increased by 16.4% in the second quarter of fiscal year 2025/2026 to CHF 251.78. The company reported a quarterly profit of CHF 236 million, offsetting the currency-related loss from the first quarter. For the first half of the current fiscal year, the company expects a profit of CHF 96 million and an increase in NAV of 6.1% in Swiss francs (17.8% in US dollars). The share price rose by 4.0% during the same period and trades at a 28% discount to NAV. The positive second quarter results are mainly attributed to developments in listed portfolio companies, including clinical study results from Abivax, Mineralys, Upstream Bio, and UniQure, as well as acquisition offers for Merus, Y-mAbs Therapeutics, and 89Bio. Foreign currency effects had no material impact on the second quarter's performance. The final half-year results will be published on October 24, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2207074_de), on October 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2572535555","isCrawlerRequest":true}